C Gosselaar

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Claartje Gosselaar
    Department of Urology Screening unit for prostate cancer, Erasmus University, Rotterdam, The Netherlands
    BJU Int 95:231-7. 2005
  2. ncbi The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:581-8. 2008
  3. ncbi The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer
    C Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 68:985-93. 2008
  4. ncbi Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 55:139-46. 2009
  5. ncbi The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    BJU Int 101:685-90. 2008
  6. ncbi Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:154-61. 2007
  7. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
  8. ncbi Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Cancer 107:2779-85. 2006
  9. ncbi Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:1053-60. 2007
  10. ncbi Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 50:475-82. 2006

Detail Information

Publications15

  1. ncbi Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Claartje Gosselaar
    Department of Urology Screening unit for prostate cancer, Erasmus University, Rotterdam, The Netherlands
    BJU Int 95:231-7. 2005
    ..The favourable characteristics of tumours detectable at very low PSA levels seem to justify the conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clinically insignificant...
  2. ncbi The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:581-8. 2008
    ..The value of digital rectal examination (DRE) as a screening test for prostate cancer (PC) is controversial in the current prostate-specific antigen (PSA) era...
  3. ncbi The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer
    C Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 68:985-93. 2008
    ....
  4. ncbi Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 55:139-46. 2009
    ..Evidence indicates that an abnormal digital rectal examination (DRE) is a risk factor for high-grade prostate cancer (PC)...
  5. ncbi The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    BJU Int 101:685-90. 2008
    ..To determine the value of a hypoechoic lesion (HL)-directed biopsy in addition to a systematic sextant biopsy for detecting prostate cancer...
  6. ncbi Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:154-61. 2007
    ..To compare tumor characteristics of screen-detected prostate cancers (PCs) either by digital rectal examination (DRE) or by prostate-specific antigen (PSA) as biopsy indication at low PSA...
  7. ncbi Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    ..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
  8. ncbi Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Cancer 107:2779-85. 2006
    ..Risk stratification of screen-detected cancers at diagnosis has become more important for the anticipation and interpretation of changing incidence/mortality ratios...
  9. ncbi Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:1053-60. 2007
    ..We present a feasibility study and impact simulation of a secondary analysis, which imitates a situation where all participants in the study are managed according to their random assignment...
  10. ncbi Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 50:475-82. 2006
    ..CONCLUSION: Only three men died of prostate cancer, none of whom were on watchful waiting. Our observations provide preliminary validation of the arbitrary selection criteria for active surveillance...
  11. ncbi Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 66:1076-81. 2006
    ..This report compares the preliminary outcome of cancers detected in the screen and the control arm of its Rotterdam section, by means of biochemical progression rates...
  12. ncbi Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population
    Stijn Roemeling
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Urol 175:1332-6. 2006
    ..The clinical presentation and prognosis of familial disease remain uncertain. In this study these entities are evaluated in the first and second rounds of a screening program in The Netherlands...
  13. ncbi Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 51:1244-50; discussion 1251. 2007
    ..To study active surveillance as a management option for the important number of prostate cancer patients who would not have been diagnosed in the absence of screening...
  14. ncbi Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 53:468-77. 2008
    ..Screening for PCa has not yet been shown to lower PCa mortality. Still, opportunistic screening is wide spread in Europe and in most other parts of the world...
  15. ncbi Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 66:625-31. 2006
    ..0 ng/ml and/or abnormal DRE/TRUS (group-1) to solely a PSA cut-off of 3.0 ng/ml (group-2). We estimated the effect of omitting DRE/TRUS by comparing the results of a re-screening 4 years after initial screening to the original policy...